Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849472 · ClinicalTrials.gov registry record · Phase 2
Treatment With Pazopanib for Neoadjuvant Breast Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT00849472 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 101 participants.
The verdict
NCT00849472, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Interventions
- PROCEDURE surgery
- DRUG doxorubicin + cyclophosphamide
- DRUG paclitaxel + pazopanib
- DRUG pazopanib monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00849472
The ClinicalTrials.gov registry entry for NCT00849472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which surgery is the first listed.
NCT00849472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00849472 about?
NCT00849472 is a clinical study titled "Treatment With Pazopanib for Neoadjuvant Breast Cancer". The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
What is the current status of trial NCT00849472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2009-07. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00849472?
The interventions under investigation include: surgery (PROCEDURE), doxorubicin + cyclophosphamide (DRUG), paclitaxel + pazopanib (DRUG), pazopanib monotherapy (DRUG).
Who is sponsoring clinical trial NCT00849472?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.